- Correspondence
- Open access
- Published:
Technical validation of controlled exposure to cat dander in the specialized particulate control environmental exposure unit (SPaC-EEU)
Allergy, Asthma & Clinical Immunology volume 21, Article number: 6 (2025)
To the Editor,
The Environmental Exposure Unit (EEU) is a 3500 square feet controlled allergen exposure facility located at the Kingston General Hospital site of Kingston Health Science Centre –in Kingston, Canada, which has been operating in this location since 1995. It is an internationally recognized model of prolonged allergen exposure, that can seat up to 120 participants at one time, with control of variables such as temperature, humidity, air flow, CO2 levels, and allergen type and concentration [1, 2]. The EEU is used to study mechanisms of, and treatments for allergic rhinitis (AR) and has been employed extensively with ragweed, grass, and birch pollens [3,4,5,6].
For the study of perennial allergens, the Specialized Particulate Control Environmental Exposure Unit (SPaC-EEU; formerly known as the house dust mite (HDM)-EEU) has been established. This is an enclosed 760 sq. ft micro-controlled room within the EEU proper, and includes an adjacent anteroom, designed to hold between 5 and 45 participants simultaneously. It has undergone technical and clinical validation for use with HDM, successfully eliciting AR symptoms and biologic changes in only HDM-allergic, and not non-allergic, participants [7, 8].
As accurate and reproducible clinical models of prolonged cat allergen exposure are limited, we sought to evaluate the SPaC-EEU for use with cat dander [9]. We hypothesized that the SPaC-EEU and its equipment are suitable for the accurate and reproducible distribution of cat allergen over time.
We sourced cat dander (Greer®, USA) with confirmed concentrations of Felis domesticus allergen 1 (Fel d 1), the most common cat allergen protein. When assessed with light and scanning electron microscopy, it was evident that the allergen could not easily be visually counted (Fig. 1A). As a result, a Fel d 1-specific enzyme-linked immunosorbent assay (ELISA; Indoor Biotechnologies, USA) was subsequently employed to quantify Fel d 1 concentrations in air samples.
Consistent Fel d 1 concentrations and particle counts were observed across runs in the Specialized Particulate Control Environmental Exposure Unit. Purchased cat dander allergen visualized under light and scanning electron microscopy (A) demonstrated a heterogenous product, whereby Fel d 1 cannot be easily visually quantified. This resulted in the use of a Fel d 1-specific ELISA to assess Fel d 1 levels in air samples, collected using sampling cassettes. Across 6 independent trial runs, defined as 2-hour sessions of cat dander distribution in the SPaC-EEU, with similar equipment setups, Fel d 1 concentrations (ng/m3) were consistent both overall (B) and in various locations of the room (C). Particles sized 2.5 μm, captured using a laser particle counter (LPC) were consistently most abundant. A strong, positive correlation (r = 0.6071, p = 0.0186) between average Fel d 1 concentration and average particle counts (D) confirms that the LPC can be used to indirectly track Fel d 1 concentrations in real-time
To assess the distribution of cat dander in the SPaC-EEU, the dander was circulated into the facility using specialized equipment, with the support of variable speed floor and ceiling fans for continuous laminar flow. Consistent with previous technical validations, trial runs were conducted as 2-hour sessions of allergen distribution, with the collection of air samples on open-faced sampling cassettes (Zefon International, USA) and particles (sized 2.5 μm, 5.0 μm, 10.0 μm, 15 μm, 20.0 μm, and 25.0 μm) using a laser particle counter (LPC) located at the centre of the room. Protein was isolated from the sampling cassettes on the day of collection and analysed with a Fel d 1-specific ELISA.
Utilizing similar equipment settings, six independent sessions in the SPaC-EEU showed consistent concentrations of Fel d 1 (p = 0.2839; Fig. 1B), with no significant differences (p = 0.4267) in concentrations observed between the front, middle, and rear of the room (Fig. 1C). There was also consistency in Fel d 1 distribution between the left, centre, and right locations of the SPaC-EEU (p = 0.8205). The most prevalent particle distributed across these runs was consistently the 2.5 μm size (Fig. 1D).
Sampling cassettes allowed us to quantify Fel d 1 concentration at the end of an exposure, whereas the LPC reports particle counts in real-time at 10-second intervals and has historically been used anecdotally to inform concentrations of distributed allergen. Four independent sessions in the SPaC-EEU were conducted, with particle data collected using the LPC and repeated air sampling using cassettes completed at 30- to 120-minute intervals. When comparing average Fel d 1 concentrations quantified from cassettes with average LPC particle counts at corresponding timepoints (Fig. 1E), we observed a significant positive correlation (r = 0.6071, p = 0.0186). This asserts the capacity for indirect monitoring of Fel d 1 concentrations in real-time using the LPC.
Lastly, we assessed the ability of rotorod impact sampling, which is used for air sampling with pollen allergens, to capture Fel d 1 concentrations. Samples were collected in two SPaC-EEU runs alongside sampling cassettes, and it was found that rotorods captured significantly lower (p < 0.05) Fel d 1 than sampling cassettes. This further reinforces the notion that the rotorod impaction method is inferior to cassettes when sampling for perennial allergens.
In summary, this technical validation confirms that the dispersal equipment in the SPaC-EEU can effectively distribute cat allergen throughout the facility in a reliable and consistent manner. The LPC has been proven to be a suitable method for indirect monitoring of real-time Fel d 1 concentrations in the SPaC-EEU, ensuring allergen dispersal consistency over time. Following this successful technical validation, the SPaC-EEU can undergo clinical validation with human participants.
Data availability
The data supporting this study are available upon request from the corresponding author.
Abbreviations
- AR:
-
Allergic Rhinitis
- EEU:
-
Environmental Exposure Unit
- ELISA:
-
Enzyme–Linked Immunosorbent Assay
- Fel d 1:
-
Felis domesticus allergen 1
- HDM:
-
House Dust Mite
- LPC:
-
Laser Particle Counter
- SPaC:
-
EEU–Specialized Particulate Control Environmental Exposure Unit
References
Hossenbaccus L, Steacy LM, Walker T, Ellis AK. Utility of environmental exposure unit challenge protocols for the study of allergic Rhinitis therapies. Curr Allergy Asthma Rep 2020 208. 2020;20(8):1–8. https://doiorg.publicaciones.saludcastillayleon.es/10.1007/S11882-020-00922-8.
Pfaar O, Bergmann KC, Bonini S, et al. Technical standards in allergen exposure chambers worldwide – an EAACI Task Force Report. Allergy. 2021;76(12):3589–612. https://doiorg.publicaciones.saludcastillayleon.es/10.1111/all.14957.
Ellis AK, Steacy LM, Hobsbawn B, Conway CE, Walker TJB. Clinical validation of controlled grass pollen challenge in the environmental exposure unit (EEU). Allergy Asthma Clin Immunol. 2015;11(1). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13223-015-0071-3.
Ellis AK, Soliman M, Steacy LM, Adams DE, Hobsbawn B, Walker TJB. Clinical validation of controlled exposure to birch pollen in the environmental exposure unit (EEU). Allergy Asthma Clin Immunol. 2016;12(1):53–53. https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13223-016-0156-7.
Day JH, Briscoe MP, Ratz JD, Ellis AK, Yao R, Danzig M. Onset of action of loratadine/montelukast in seasonal allergic rhinitis subjects exposed to ragweed pollen in the environmental exposure unit. Allergy Asthma Proc. 2009;30(3):270–6. https://doiorg.publicaciones.saludcastillayleon.es/10.2500/aap.2009.30.3234.
Ellis AK, Frankish CW, O’Hehir RE, et al. Treatment with grass allergen peptides improves symptoms of grass pollen–induced allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2017;140(2):486–96. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.jaci.2016.11.043.
Hossenbaccus L, Linton S, Thiele J, et al. Clinical validation of controlled exposure to house dust mite in the environmental exposure unit (EEU). Allergy Asthma Clin Immunol off J Can Soc Allergy Clin Immunol. 2021;17:34. https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13223-021-00536-3.
Walker TJ, Steacy LM, Ellis AK. Preliminary Proof of House Dust Mite distribution capability in the environmental exposure unit. J Allergy Clin Immunol. 2017;139(2):AB119–119. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.jaci.2016.12.382.
Hossenbaccus L, Linton S, Ramchandani R, Burrows AG, Ellis AK. Study of Cat Allergy Using Controlled Methodology—A Review of the Literature and a Call to Action. Front Allergy. 2022;3. Accessed June 3, 2023. https://www.frontiersin.org/articles/https://doiorg.publicaciones.saludcastillayleon.es/10.3389/falgy.2022.828091
Acknowledgements
The authors would like to thank Jenny Thiele for her guidance in the early stages of this technical validation.
Funding
Self funded by the Kingston Allergy Research Trust.
Author information
Authors and Affiliations
Contributions
LH performed the sample and data analyses and drafted the manuscript. TW was responsible for all operations related to the SPaC-EEU and reviewed the manuscript. AKE oversaw the study and ensured critical revision of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
No applicable.
Competing interests
In the past 36 months, Dr. Anne K. Ellis has participated in advisory boards for ALK Abello, AstraZeneca, Bausch Health, LEO Pharma, Miravo, Merck, Novartis, has been a speaker for ALK Abello, AstraZeneca, Bausch, Miravo, Medexus, Mylan, Novartis, Pfizer, Sanofi, StallergenesGreer and Regeneron. Her institution has received research grants from ALK Abello, Aralez, AstraZeneca, Bayer LLC, Medexus, Novartis, Sanofi and Regeneron. She has also served as an independent consultant to Bayer LLC, Pharming, and Regeneron.The other authors have nothing to declare. The other authors have nothing to declare.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Hossenbaccus, L., Walker, T. & Ellis, A.K. Technical validation of controlled exposure to cat dander in the specialized particulate control environmental exposure unit (SPaC-EEU). Allergy Asthma Clin Immunol 21, 6 (2025). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13223-024-00928-1
Received:
Accepted:
Published:
DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13223-024-00928-1